Regulatory
Antimicrobial manufacturers may need prior approval as India moves to tighten regulations
The move comes amid mounting concerns over antimicrobial resistance
- By IPP Bureau
| November 22, 2026
India is moving to tighten regulatory oversight of antimicrobial products, proposing to bring them under the definition of ‘New Drug’ and make prior approval from the Central Licensing Authority (CLA) mandatory before manufacturers can apply for manufacturing licences.
The Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, through a draft Gazette notification. The proposal seeks to include ‘antimicrobials’ under Rule 2(1)(w)(v) of the rules, bringing these products within the regulatory framework applicable to new drugs.
The move comes amid mounting concerns over antimicrobial resistance (AMR), a major global public health threat that requires coordinated action. The G20 New Delhi Leaders’ Declaration had also highlighted the need to tackle AMR through a One Health approach.
A key concern driving the proposed amendment is the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny. The Ministry has flagged gaps in mandatory assessments, including bioavailability/bioequivalence and stability studies, which are critical to establishing the quality, safety and efficacy of drug products.
The absence of such assessments could allow substandard or ineffective antimicrobials to enter the market, potentially accelerating the development and spread of antimicrobial resistance and putting patient safety at risk.
Under the proposed changes, manufacturers would have to secure permission from the Central Licensing Authority before approaching the concerned State Licensing Authority (SLA) for a manufacturing licence. This would introduce an additional layer of central scrutiny and bring antimicrobial products under tighter regulatory control.
The proposed framework is intended to strengthen quality checks and ensure that antimicrobial products meet the required standards of safety, quality and efficacy before manufacturing licences are granted.
The draft notification has been issued for public consultation, inviting objections and suggestions from stakeholders and members of the public. The central government will consider the feedback before taking a final call on the proposed amendment.